Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 2/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10871210 | 0.72 | P2RX4 (0.33) | P2RX4P2RX1P2RX3P2RX7BCHE | |
| SCHEMBL8439081 | 0.72 | P2RX4 (0.33) | P2RX4P2RX1P2RX3P2RX7BCHE | |
| SCHEMBL42610 | 0.71 | TSHR (0.32) | — | |
| SCHEMBL1552556 | 0.71 | — | — | |
| SCHEMBL42466 | 0.69 | P2RX4 (0.32) | P2RX4P2RX1P2RX3P2RX7BCHE | |
| SCHEMBL42467 | 0.69 | TP53 (0.39) | P2RX4P2RX1P2RX3P2RX7BCHE | |
| SCHEMBL82497 | 0.69 | TSHR (0.33) | P2RX4P2RX1P2RX3P2RX7BCHE | |
| SCHEMBL6226780 | 0.67 | TP53 (0.32) | TP53 | |
| SCHEMBL7778347 | 0.67 | ALDH1A1 (0.36) | BCHETP53 | |
| SCHEMBL23982597 | 0.67 | P2RX4 (0.31) | P2RX4P2RX1P2RX3P2RX7BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026088-B | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| EP-3325475-B1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-18 | — | — | EP | disclosed |
| EP-2939675-B1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10308643-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-11 | — | — | US | disclosed |
| EP-3325475-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| WO-2017014321-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| US-20170015655-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| EP-0474561-A1 | Arylalkylamines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-03-11 | — | — | EP | disclosed |
| EP-0428434-A2 | Compounds of aromatic amines and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1991-05-22 | — | — | EP | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| US-4696931-A | CARDIOVASCULAR DISORDERS, CARDIOTONIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-09-29 | — | — | US | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
| US-4582837-A | Imidazo[4,5-b] and [4,5-c]pyridine derivatives having cardiotonic activity | DR. KARL THOMAE GMBH (DE) | 1986-04-15 | — | — | US | disclosed |
| EP-0098448-A2 | Imidazole derivatives, their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SLCO1B3, SLC22A8, SLCO4C1 | P2RX4 667/4885P2RX1 983/4885P2RX3 317/4885 |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SLCO1B3, SLC22A8, SLCO4C1 | P2RX4 667/4885P2RX1 983/4885P2RX3 317/4885 |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | P2RX4 172/4885P2RX1 229/4885P2RX3 208/4885 |
| US-20170015655-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC11, HDAC5 | P2RX4 3697/4885P2RX1 3281/4885P2RX3 3102/4885 |
| US-10308643-B2 | Heterocyclic compound | HDAC1, HDAC11, HDAC5 | P2RX4 3697/4885P2RX1 3281/4885P2RX3 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.